Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Are the Latest Market Insights for the Anti-Vascular Endothelial Growth Factor Therapeutics Industry?

In recent times, the market size of anti-vascular endothelial growth factor therapeutics has seen a slight decline. However, it is projected to expand from “$12.2 billion in 2024 to $12.17 billion in 2025, experiencing a compound annual growth rate (CAGR) of -0.2%”. The growth experienced in the past years has implications from the surge in age-related macular degeneration, an increase in cases of diabetic retinopathy, advancements in the diagnosis of retinal disease, successful clinical outcomes and efficiency, as well as the transition to outpatient treatment.

In the upcoming several years, the market for anti-vascular endothelial growth factor therapeutics is predicted to experience incremental growth, advancing to “$13.17 billion in 2029 with a compound annual growth rate (CAGR) of 2.0%. The market’s growth for the projected period can be owed to factors such as an aging population and widespread ocular diseases, widening uses in treating retinal disorders, creation of next-gen therapeutics, heightened focus on early intervention, worldwide health drives, and treatment accessibility. The trending dynamics within the forecast period include increased use in cancer therapy, attention towards combined therapies in the field of ophthalmology, experimentation on biosimilar versions, studies on resistance mechanisms, and integration with imaging technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=10683&type=smp

What Forces Are Driving The Growth Of The Anti-Vascular Endothelial Growth Factor Therapeutics Industry?

The rise in the incidence of ocular disorders is anticipated to accelerate the growth of the anti-vascular endothelial growth factor therapeutics market. The term ‘incidence of ocular diseases’ refers to the quantity or ratio of individuals in a particular population diagnosed with or portraying distinct eye ailments. Anti-vascular endothelial growth factor (VEGF) treatments help mitigate the incidence of ocular disorders by effectively managing conditions such as wet age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion. The World Health Organization reported in October 2022, for example, that approximately 2.2 billion individuals worldwide suffer from mild or severe visual impairment, with 1 billion experiencing distance vision problems. Additionally, of those affected, about 88.4 million are dealing with refractive error, 94 million with cataracts, 8 million with age-related macular degeneration, and approximately 3.9 million with diabetic retinopathy. Hence, the escalating occurrence of ocular diseases is fuelling the expansion of the anti-vascular endothelial growth factor therapeutics market.

What Is The Overview Of Market Segmentation In The Anti-Vascular Endothelial Growth Factor Therapeutics Industry?

The anti-vascular endothelial growth factor therapeutics market covered in this report is segmented –

1) By Product: Eylea, Lucentis, Beovu

2) By Disease: Macular Edema, Diabetic Retinopathy, Retinal Vein Occlusion, Age-related Macular Degeneration

3) By End Users: Hospitals, Clinics, Oncology Centers, Other End Users

Subsegments:

1) By Eylea: Indications, Dosage Forms

2) By Lucentis: Indications, Dosage Forms

3) By Beovu: Indications, Dosage Forms

What Trends Are Currently Influencing Growth In The Anti-Vascular Endothelial Growth Factor Therapeutics Market?

Innovations in treatment methods are emerging as a notable trend in the anti-vascular endothelial growth factor therapeutics market. Businesses in this market are employing cutting-edge therapeutic techniques to maintain their competitiveness. For example, Ashvattha Therapeutics Inc., an American clinical-stage biopharmaceutical business, revealed phase 1 safety information in May 2022 for healthy participants for subcutaneous anti-VEGF wet AMD (age-related macular degeneration) and DME (diabetic macular edema) candidates. The innovative D-4517.2 therapy is a trailblazer, created to address the shortcomings in curing DME conditions. On top of being a pioneer, D-4517.2 therapy is designed for do-it-yourself administration using an autoinjector. The usage of autoinjector D-4517.2 ensures that patients can apply the medication themselves every month in the familiar surroundings of their residences.

Who Are The Primary Players Operating Across The Global Anti-Vascular Endothelial Growth Factor Therapeutics Market?

Major companies operating in the anti-vascular endothelial growth factor therapeutics market include F. Hoffmann-La Roche AG, Biogen Inc., Pfizer Inc., Coherus BioSciences Inc., Eli Lilly and Company, Bausch Health Companies Inc., Viatris Inc., Xbrane Biopharma AB, Bayer AG, Regeneron Pharmaceuticals Inc., Genentech Inc, Allergan Inc., Novartis AG, kyowa Kirin Co. Ltd., Amgen Inc., AstraZeneca plc, Merck & Co. Inc., Johnson & Johnson Private Limited, Sanofi S.A., AbbVie Inc., Takeda Pharmaceutical Company Limited, Astellas Pharma Inc., Bristol-Myers Squibb Company, Boehringer Ingelheim International GmbH, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Vertex Pharmaceuticals Incorporated, Alexion Pharmaceuticals Inc.

Get The Full Report Here:

https://www.thebusinessresearchcompany.com/report/anti-vascular-endothelial-growth-factor-therapeutics-global-market-report

Which Region Offers The Most Growth Potential For The Anti-Vascular Endothelial Growth Factor Therapeutics Market Through 2029?

North America was the largest region in the anti-vascular endothelial growth factor therapeutics market in 2024.Europe is expected to be the fastest-growing region in the global anti-vascular endothelial growth factor therapeutics market report during the forecast period. The regions covered in the anti-vascular endothelial growth factor therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=10683&type=smp

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795

Asia +44 7882 955267 & +91 8897263534

Europe +44 7882 955267

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model